Literature DB >> 31290933

Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.

Colette DeJong1, Dhruv S Kazi2, R Adams Dudley1, Randi Chen3, Chien-Wen Tseng3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31290933      PMCID： PMC6624798          DOI： 10.1001/jamacardio.2019.2223

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  5 in total

1.  2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Monica M Colvin; Mark H Drazner; Gerasimos Filippatos; Gregg C Fonarow; Michael M Givertz; Steven M Hollenberg; JoAnn Lindenfeld; Frederick A Masoudi; Patrick E McBride; Pamela N Peterson; Lynne Warner Stevenson; Cheryl Westlake
Journal:  Circulation       Date:  2016-05-20       Impact factor: 29.690

2.  Full coverage for preventive medications after myocardial infarction.

Authors:  Niteesh K Choudhry; Jerry Avorn; Robert J Glynn; Elliott M Antman; Sebastian Schneeweiss; Michele Toscano; Lonny Reisman; Joaquim Fernandes; Claire Spettell; Joy L Lee; Raisa Levin; Troyen Brennan; William H Shrank
Journal:  N Engl J Med       Date:  2011-11-14       Impact factor: 91.245

Review 3.  Epidemiology and risk profile of heart failure.

Authors:  Anh L Bui; Tamara B Horwich; Gregg C Fonarow
Journal:  Nat Rev Cardiol       Date:  2010-11-09       Impact factor: 32.419

4.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

5.  Adoption of Sacubitril/Valsartan for the Management of Patients With Heart Failure.

Authors:  Lindsey R Sangaralingham; S Jeson Sangaralingham; Nilay D Shah; Xiaoxi Yao; Shannon M Dunlay
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790
  5 in total
  11 in total

1.  Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure.

Authors:  Andrew Sumarsono; Muthiah Vaduganathan; Ezimamaka Ajufo; Ann Marie Navar; Gregg C Fonarow; Sandeep R Das; Ambarish Pandey
Journal:  JAMA Cardiol       Date:  2020-03-01       Impact factor: 14.676

2.  Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions.

Authors:  Birju R Rao; Neal W Dickert; Alanna A Morris; Candace D Speight; Graham H Smith; Supriya Shore; Miranda A Moore
Journal:  Circ Heart Fail       Date:  2020-11-12       Impact factor: 8.790

3.  Understanding the Complexity of Heart Failure Risk and Treatment in Black Patients.

Authors:  Aditi Nayak; Albert J Hicks; Alanna A Morris
Journal:  Circ Heart Fail       Date:  2020-08-13       Impact factor: 8.790

4.  Show Me the Money: Patients' Perspectives on a Decision Aid for Sacubitril/Valsartan Addressing Out-of-Pocket Cost.

Authors:  Neal W Dickert; Andrea R Mitchell; Grace E Venechuk; Daniel D Matlock; Miranda A Moore; Alanna A Morris; Kenneth J Pierce; Candace D Speight; Larry A Allen
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-12-11

5.  Missed opportunities in medical therapy for patients with heart failure in an electronically-identified cohort.

Authors:  Amrita Mukhopadhyay; Harmony R Reynolds; Arielle R Nagler; Lawrence M Phillips; Leora I Horwitz; Stuart D Katz; Saul Blecker
Journal:  BMC Cardiovasc Disord       Date:  2022-08-04       Impact factor: 2.174

Review 6.  Psychological stress in heart failure: a potentially actionable disease modifier.

Authors:  Kristie M Harris; Daniel L Jacoby; Rachel Lampert; Richard J Soucier; Matthew M Burg
Journal:  Heart Fail Rev       Date:  2020-11-20       Impact factor: 4.214

7.  Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.

Authors:  Nicolas Isaza; Paola Calvachi; Inbar Raber; Chia-Liang Liu; Brandon K Bellows; Inmaculada Hernandez; Changyu Shen; Michael C Gavin; A Reshad Garan; Dhruv S Kazi
Journal:  JAMA Netw Open       Date:  2021-07-01

8.  Coverage, Formulary Restrictions, and Out-of-Pocket Costs for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists in the Medicare Part D Program.

Authors:  Jing Luo; Robert Feldman; Scott D Rothenberger; Inmaculada Hernandez; Walid F Gellad
Journal:  JAMA Netw Open       Date:  2020-10-01

Review 9.  The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction.

Authors:  Nicholas K Brownell; Boback Ziaeian; Gregg C Fonarow
Journal:  Card Fail Rev       Date:  2021-11-26

10.  Out-of-Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States.

Authors:  Stephen Y Wang; Javier Valero-Elizondo; Hyeon-Ju Ali; Ambarish Pandey; Miguel Cainzos-Achirica; Harlan M Krumholz; Khurram Nasir; Rohan Khera
Journal:  J Am Heart Assoc       Date:  2021-05-16       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.